Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge by Chris A. R. Baker, Louise Swainson, Din L.

Slides:

Advertisements

Similar presentations

Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies by Xiangguo Qiu, Jonathan Audet, Gary Wong, Stephane Pillet,

Advertisements

Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates by Gary Wong, Jason S. Richardson, Stéphane.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

G. Pialoux, C. Delaugerre, L. Cotte, F. Raffi, E. Cua, J.-M. Molina

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 7 Correlation of NHP and human ISGs.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Filipin staining of marginal gyrus of cerebral cortex in NPC cats

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 2. Deficiency of neuronal HS leads to reduced neuroinflammation.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Fig. 5. Col IV–Ac2-26 NPs decrease lesion area, necrotic area, and oxidative stress in brachiocephalic arterial plaques. Col IV–Ac2-26 NPs decrease lesion.

Colonization in tumor models and different modes of administration

Fig. 5. Vitamin B12 supplementation in the host altered the transcriptome of P. acnes in the skin microbiota. Vitamin B12 supplementation in the host altered.

Fig. 3. Increased expression of exhaustion markers and apoptosis markers on CAR8 cells in the presence of TCR antigen. Increased expression of exhaustion.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

The microchip-based drug delivery device and overview of study design

Fig. 1. A model to explain the pleiotropy of CEP290 disease.

Fig. 6. Prolonged miR overexpression in the adult heart reduces fibrotic scar size but compromises cardiac function after MI. Prolonged miR

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent. In vivo tumor responses are mechanism of action–specific.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Nanoimmunotherapy production scale-up and evaluation in Apoe−/− mice

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model by Beth D. Kirkpatrick, Stephen S. Whitehead,

Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 2. PlGF-2123–144 conjugation reduces systemic exposure to checkpoint blockade Abs and potential treatment-related toxicity. PlGF-2123–144 conjugation.

Fig. 2 NDR2-deficient mice are more vulnerable to RNA viral infection.

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

by Peter Bacchetti, Steven G. Deeks, and Joseph M. McCune

Fig. 2 Neonatal ZIKV infection induces seizures in young mice and increases susceptibility to chemically induced seizures in adult mice. Neonatal ZIKV.

Fig. 6. Confocal image series at 10-μm intervals through the full retinal thickness at P48 in WT and vldlr-null mice. Confocal image series at 10-μm intervals.

Fig. 3 Viral loads and viral DNA in anti-α4β7 antibody–treated rhesus macaques that initiated ART during chronic SIVmac251 infection (study 2). Viral loads.

Fig. 4 S. elongatus therapy does not elicit a pathologic immune response nor persist in tissue long-term. S. elongatus therapy does not elicit a pathologic.

Fig. 1 Study design and antibody pharmacokinetics.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Two-mAb cocktail protects macaques against the Makona variant of Ebola virus by Xiangguo Qiu, Jonathan Audet, Ming Lv, Shihua He, Gary Wong, Haiyan Wei,

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

Fig. 1 ZMAb improves survival of EBOV-challenged NHPs

Fig. 7 BEL immune response.

Kaplan–Meier plots of survival by gestational week for babies born at 23–26 weeks of gestation in level 3 and level 2 centres in England in Kaplan–Meier.

Fig. 3. miR overexpression leads to increased cell proliferation as well as altered differentiation and metabolism in cardiomyocytes. miR

© The Author(s) Published by Science and Education Publishing.

Fig. 3 Anticipated transmission dynamics under scenarios of vaccine escape and vaccine waning. Anticipated transmission dynamics under scenarios of vaccine.

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

Fig. 2. Col IV–Ac2-26 NPs increase subendothelial collagen in Ldlr−/− mice with established atherosclerosis. Col IV–Ac2-26 NPs increase subendothelial.

Fig. 5 LASV replication in cynomolgus monkeys.

Fig. 3. Association between peak CTL019 expansion and response.

Fig. 1. APP/PS1;C3 KO mice show improved cognitive flexibility (reversal) compared to APP/PS1 mice at 16 months of age. APP/PS1;C3 KO mice show improved.

Fig. 3. Col IV–Ac2-26 NPs suppress lesional superoxide and increase lesional Il10 mRNA in Ldlr−/− mice with established atherosclerosis. Col IV–Ac2-26.

Fig. 6 TNF-α neutralization prevents ZIKV-induced seizures in mice.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Fig. 1 Generation and characterization of MeV-based vaccine candidates for Lassa virus. Generation and characterization of MeV-based vaccine candidates.

Fig. 6 Pharmacologic alterations of β-AR signaling regulate cardiomyocyte abscission and endowment. Pharmacologic alterations of β-AR signaling regulate.

Fig. 8 Immune correlates of protection.

Fig. 3 Postnatal assembly of the humanized gut microbiota.

Fig. 6. Connectivity and mobility maps for Lesotho.

Presentation transcript:

Exposure to SIV in utero results in reduced viral loads and altered responsiveness to postnatal challenge by Chris A. R. Baker, Louise Swainson, Din L. Lin, Samson Wong, Dennis J. Hartigan-O’Connor, Jeffrey D. Lifson, Alice F. Tarantal, and Joseph M. McCune Sci Transl Med Volume 7(300):300ra125-300ra125 August 12, 2015 Copyright © 2015, American Association for the Advancement of Science

Fig. 1. Study design. Study design. (A) Timeline of immunizations and virus challenges. Fetal macaques were injected with SIVmac1A11 or PBS in the late first trimester (55 ± 5 days gestation; term 165 ± 10 days). Animals were then delivered by cesarean section at full term and immunized with either PBS or SIV antigens as neonates. At 16 weeks postnatal age, each animal was orally challenged with SIVmac239. Animals that did not demonstrate productive infection were then challenged intravenously between 37 and 57 weeks of age with SIVmac239 and followed for disease progression. IV, intravenous. (B) Summary of study groups. Chris A. R. Baker et al., Sci Transl Med 2015;7:300ra125 Copyright © 2015, American Association for the Advancement of Science